Physician profile
Robert R Perry
NPI 1841272481
$2,275.25
in general payments reported to CMS, 2019-2025
30 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $132 · 2021: $156 · 2022: $345 · 2023: $420 · 2024: $543 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $223.54 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $196.57 | 2022-2025 | |
| Abbvie INC. | $159.56 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $139.47 | 2022-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $120.43 | 2021-2024 | Proclaim |
| Astellas Pharma US INC | $112.95 | 2024-2025 | Veozah |
| Dexcom, INC. | $103.60 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $101.64 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Corcept Therapeutics | $80.14 | 2024-2025 | Korlym |
| Allergan, INC. | $75.60 | 2019-2020 | |
| Hologic Sales and Service, LLC | $65.61 | 2025 | Aptima |
| Novartis Pharmaceuticals Corporation | $63.07 | 2019-2023 | |
| Amgen INC. | $52.81 | 2023-2025 | Repatha, Otezla, Evenity |
| Regeneron Healthcare Solutions, INC. | $52.18 | 2024 | Libtayo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $41.74 | 2022-2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $36.62 | 2021-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.06 | 2020-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.82 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $30.36 | 2025 | Inspire |
| Lundbeck LLC | $30.18 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $21.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.44 | 2023 | Quviviq |
| Nevro Corp. | $19.84 | 2023 | Senza |
| Corium, LLC | $18.94 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $16.75 | 2023 | Eliquis |
| Electromed, INC. | $15.85 | 2023 | Smartvest |
| Sanofi-Aventis U.S. LLC | $15.69 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.07 | 2024 | Xifaxan |
| Exact Sciences Corporation | $14.79 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.